Back to top
more

Asterias Biotherapeutics, Inc. (AST)

(Delayed Data from AMEX)

$NA USD

NA
NA

0 (0.00%)

Updated Mar 7, 2019 03:57 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

What Makes Asterias Biotherapeutics (AST) a New Buy Stock

by Zacks Equity Research

Asterias Biotherapeutics (AST) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Achillion Reports Positive Interim Data on Factor D Inhibitors

by Zacks Equity Research

Achillion's (ACHN) shares rise following the announcement of positive interim data from early to mid-stage studies evaluating its factor D inhibitors ??? ACH-4471, ACH-5228 and ACH-5548.

Asterias Biotherapeutics (AST) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Asterias Biotherapeutics (AST) delivered earnings and revenue surprises of 20.00% and 10.48%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

Are Options Traders Betting on a Big Move in Asterias Biotherapeutics (AST) Stock?

by Zacks Equity Research

Investors in Asterias Biotherapeutics (AST) need to pay close attention to the stock based on moves in the options market lately.

    Asterias Biotherapeutics (AST) Reports Q2 Loss, Tops Revenue Estimates

    by Zacks Equity Research

    Asterias Biotherapeutics (AST) delivered earnings and revenue surprises of 0.00% and 3.81%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

      Achillion's 3rd Factor D Inhibitor Enters Clinical Studies

      by Zacks Equity Research

      Achillion (ACHN) commences a first-in-human phase I study on ACH-5548, a next-generation, oral small-molecule factor D inhibitor.

        VIVUS, Inc. (VVUS) Soars: Stock Adds 10.1% in Session

        by Zacks Equity Research

        VIVUS (VVUS) was a big mover last session, as the company saw its shares rise more than 10% on the day, amid huge volumes.

          Asterias Biotherapeutics Sees Hammer Chart Pattern: Time to Buy?

          by Zacks Equity Research

          Asterias Biotherapeutics Sees Hammer Chart Pattern: Time to Buy?

            Are Options Traders Betting on a Big Move in Asterias Biotherapeutics (AST) Stock?

            by Zacks Equity Research

            Investors in Asterias Biotherapeutics (AST) need to pay close attention to the stock based on moves in the options market lately.

              Implied Volatility Surging for Asterias Biotherapeutics (AST) Stock Options

              by Zacks Equity Research

              Asterias Biotherapeutics (AST) warrants investors' attention based on moves in the options market lately.

                3 Healthcare Stocks Poised to Beat Q2 Earnings

                by Zacks Equity Research

                in the second quarter, results have managed to outpace expectations so far.